http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories
-
Entera Bio EB613 phase 2 data selected for ASBMR 2026 plenary
-
Entera Bio Phase 2 Data Supporting EB613’s (Oral PTH(1-34)) Anabolic Effect on Postmenopausal Women with Osteoporosis at High Risk for Fracture Selected for Plenary Poster Session Presentation at th
-
Entera Bio to Participate in the Canaccord Genuity 46th Annual Growth Conference
-
Entera Bio prices $275M private placement led by BVF Partners
-
Entera Bio prices $275 million private placement led by BVF Partners
-
Entera Bio Announces Pricing of Oversubscribed $275 Million Private Placement
-
Entera Bio Announces Pricing of Oversubscribed $275 Million Private Placement
-
FDA backs Entera Bio's Phase 3 trial plan for oral osteoporosis drug
-
Entera Bio Receives Positive FDA Feedback on 12-Month Registrational Phase 3 Study for EB613 - the First Oral Anabolic Tablet in Development for Postmenopausal Women with Osteoporosis
-
ENTERA BIO shares preclinical data for two pipeline drugs at ENDO 2026
-
Entera Reports Robust Preclinical Data for EB612 (Oral LA-PTH(1-34)) for Hypoparathyroidism and EB618 (Oral GLP-1/Glucagon) for Obesity at ENDO 2026
-
Entera reports comparable results for single-tablet EB613 versus injection
-
ENDO 2026 Oral Presentation Highlights Comparative Clinical Data for Entera’s Breakthrough Single Tablet EB613 (First-in-Class Oral PTH(1-34) Anabolic for Osteoporosis)
-
ENDO 2026 Oral Presentation Highlights Comparative Clinical Data for Entera’s Breakthrough Single Tablet EB613 (First-in-Class Oral PTH(1-34) Anabolic for Osteoporosis)
-
Entera Bio's EB613 data selected for presentation at ENDO 2026
-
Entera’s EB613, First-in-Class Oral PTH(1-34) Anabolic for Osteoporosis - Single Tablet Data Selected for Late Breaking Oral Presentation at ENDO 2026 Annual Meeting; Additional Oral Peptide Pipelin
-
Entera Announces First Quarter 2026 Financial Results and Updates Across its Oral Peptide Programs
-
Entera Bio to Host Key Opinion Leader Webinar Highlighting the Osteoporosis Treatment Landscape and the Opportunity for EB613
-
Entera Bio raises $10 million from BVF Partners in private placement
-
Entera Bio Announces Pricing of $10.0 Million Direct Investment by BVF Partners with Potential for up to $24.5 Million in Total Proceeds
-
Entera Bio Announces Full Year 2025 Financial Results and Provides Business Updates
-
Entera Bio submits streamlined Phase 3 protocol for oral osteoporosis drug
-
Entera Bio Submits Streamlined Phase 3 Protocol to Initiate Registrational Program for EB613 in Postmenopausal Women with Osteoporosis
-
Entera Bio to Participate in the Leerink Partners 2026 Global Healthcare Conference
-
Entera Bio to Participate in the Leerink Partners 2026 Global Healthcare Conference
-
Entera Bio board members purchase shares in open market transactions
-
Entera Bio Announces Open Market Purchases of Company Stock by Board Members
-
Entera Bio names former Pfizer executive as new chairman
-
Entera Bio Appoints Former Pfizer Executive Geno J. Germano as Chairman of the Board Ahead of Key Milestones
-
OPKO Health and Entera Bio expand partnership for oral PTH tablet
-
OPKO Health and Entera Bio Expand Partnership to Advance First-in-Class Oral Long Acting PTH Tablet for Patients with Hypoparathyroidism
-
Entera Bio outlines Q1 2026 milestones for osteoporosis drug
-
Entera Bio Announces Upcoming Q1 2026 Corporate Priorities and Pipeline Outlook
-
Entera Bio Announces Upcoming Q1 2026 Corporate Priorities and Pipeline Outlook
-
Entera Bio Congratulates the FNIH-ASBMR-SABRE Team on FDA’s Qualification of Total Hip BMD as Regulatory Endpoint: Huge Win for Osteoporosis Innovation
-
Entera Bio reports preclinical data for once-daily hypoparathyroidism tablet
-
Entera Bio Announces New Data Supporting Further Development of a Proprietary First-in-Class Oral, Long-Acting PTH Tablet for Patients with Hypoparathyroidism (EB612 Program)
-
Entera Bio to Participate in the 8th Annual Evercore ISI Healthcare Conference
-
Entera Bio Announces Third Quarter 2025 Financial Results and Business Updates
-
Entera Bio reports bone density gains in early menopause trial
-
Entera Bio Presents Positive New Clinical Data from EB613 Phase 2 Trial Demonstrating Significant Bone Density Improvements in Early Postmenopausal Women
-
Entera Bio to present EB613 osteoporosis data at menopause conference
-
Entera Bio to Present New Clinical Data from Phase 2 Trial of EB613 at the 2025 North American Menopause Society (NAMS) Annual Meeting
-
Entera Bio presents oral GLP-2 tablet data at medical conference
-
Entera Bio Reports Positive PK Data for First-in-Class Oral GLP-2 Tablet Treatment for Patients with Short Bowel Syndrome at the 2025 ESPEN Congress
-
Entera Bio presents bone density improvements from EB613 osteoporosis drug
-
Entera Bio Presents Positive Effects of EB613 on Both Trabecular and Cortical Bone in Postmenopausal Women with Osteoporosis at ASBMR 2025
-
Entera Bio to present clinical data at September medical conferences
-
Entera Bio to Unveil Clinical and Non-Clinical Data Across 3 Oral Peptide Programs at Upcoming September Conferences
-
Entera Bio Announces Second Quarter 2025 Financial Results and Business Updates
